Long Shortz with Clever Culture Systems: Automating microbiology for big pharma

Tylah Tully chats with Clever Culture Systems (ASX:CC5) CEO and managing director Brent Barnes about the company’s innovative technology that digitises microbiology for some of the world’s largest pharmaceutical companies, including AstraZeneca, Bristol Myers Squibb, and Novo Nordisk.

Barnes explains how their APAS system automates the detection of microbial growth on culture plates, improving efficiency, traceability, and quality in sterile drug manufacturing.

The discussion also covers the launch of their new contact plate automation, the expanding pharmaceutical manufacturing market, and what investors can expect from the company in the near future.

Watch the video for more.

This video was developed in collaboration with Clever Culture Systems, a Stockhead client at the time of publishing.

The interviews and discussions in this video are opinions only and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.